Investor
Every published round Ceres Capital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Ceres Capital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Ceres Capital, as distinct from the investments it has made.
Companies Ceres Capital has backed that another company then bought. An exit for the holding, not a deal Ceres Capital did.
| Name | Role | Sources |
|---|---|---|
| Sam Brougham | Director | Startup Daily, Mumbrella |
Stories naming Ceres Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup of four Australian raises: Firmus Technologies' US$2 billion round at a $15 billion valuation, Eudaemon's $3.75 million, Zabidou's $3.5 million seed round, and Rampart's $2.3 million.
SYNthesis BioVentures' third investor letter reports a roughly A$7.5m first close for Alzheimer's biotech S2N, lists co-investors, and profiles managing director Amir's career across OneVentures, Ceres Capital and other life-sciences roles.